Search for 'Provider:Schizophrenia Research,'

Facial affect recognition in early and late-stage schizophrenia patients.

By Rodríguez Torresano, Javier | Palomo Álvarez, Tomás | Rodríguez Jiménez, Roberto. Schizophrenia research, 2016 . 72(1-3):177-83. , Formato Vancouver: Romero Ferreiro MV, Aguado L, Rodríguez Torresano J, Palomo T, Rodríguez Jimenez R, Pedreira Massa JL. Facial affect recognition in early and late-stage schizophrenia patients. Schizophr Res. 2016 Apr;172(1-3):177-83.

Place Hold on Facial affect recognition in early and late-stage schizophrenia patients.

The MCCB impairment profile in a Spanish sample of patients with schizophrenia: Effects of diagnosis, age, and gender on cognitive functioning.

By Rodríguez Jiménez, Roberto | Dompablo Tobar, Mónica | Bagney Lifante, Alexandra | Torio, Iosune | Moreno Ortega, Marta | Jiménez Arriero, Miguel Ángel | Palomo Álvarez, Tomás. Schizophrenia research, 2015 . 169(1-3):116-120. , Formato Vancouver: Rodríguez Jiménez R, Dompablo M, Bagney A, Santabárbara J, Aparicio AI, Torio I et al. The MCCB impairment profile in a Spanish sample of patients with schizophrenia: Effects of diagnosis, age, and gender on cognitive functioning. Schizophr Res. 2015 Dec;169(1-3):116-120.

Place Hold on The MCCB impairment profile in a Spanish sample of patients with schizophrenia: Effects of diagnosis, age, and gender on cognitive functioning.

Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study.

By Rodríguez Jiménez, Roberto. Schizophrenia research, 2015 . 164(1-3):65-73. , Formato Vancouver: Cuesta MJ, Sánchez Torres AM, Cabrera B, Bioque M, Merchán Naranjo J, Corripio I et al; PEPs Group. Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study. Schizophr Res. 2015 May;164(1-3):65-73.

Place Hold on Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study.

Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia.

By Taboada, Diana | Aragüés Figuero, María | Sanz Fuentenebro, Francisco Javier. Schizophrenia research, 2014 . 158(1-3):223-9. , Formato Vancouver: Molina V, Taboada D, Aragüés M, Hernández JA, Sanz-Fuentenebro J. Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia. Schizophr Res. 2014 Sep;158(1-3):223-9.

Place Hold on Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia.

Cognition and the five-factor model of the Positive and Negative Syndrome Scale in schizophrenia.

By Bagney Lifante, Alexandra | Díez Martín, Justo | Jiménez Arriero, Miguel Ángel | Martínez Gras, María Isabel | Mesa Rodas, Natalia | Palomo Álvarez, Tomás | Rodríguez Jiménez, Roberto. Schizophrenia Research, 2013 . 143(1):77-83. , Formato Vancouver: Rodríguez-Jiménez R, Bagney A, Mezquita L, Martinez-Gras I, Sánchez-Morla EM, Mesa N et al. PARG. Cognition and the five-factor model of the positive and negative syndrome scale in schizophrenia. Schizophr Res. 2013 Jan;143(1):77-83.

Place Hold on Cognition and the five-factor model of the Positive and Negative Syndrome Scale in schizophrenia.

Randomized trial of clozapine vs. risperidone in treatment-naive first-episode schizophrenia: Results after one year.

By Aragüés Figuero, María | Palomo Álvarez, Tomás | Sanz Fuentenebro, Francisco Javier | Taboada, Diana. Schizophrenia Research, 2013 . 149(1-3):156-61. , Formato Vancouver: Sanz-Fuentenebro J, Taboada D, Palomo T, Aragües M, Ovejero S, Del Alamo C et al. Randomized trial of clozapine vs. risperidone in treatment-naïve first-episode schizophrenia: results after one year. Schizophr Res. 2013 Sep;149(1-3):156-61.

Place Hold on Randomized trial of clozapine vs. risperidone in treatment-naive first-episode schizophrenia: Results after one year.

Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes.

By Leza, Juan Carlos | Mac-Dowell, Karina Soledad. Schizophrenia Research, 2012 . 137(1-3):66-72. , Formato Vancouver: Martínez-Cengotitabengoa M, Mac-Dowell KS, Leza JC, Micó JA, Fernandez M, Echevarría E et al. Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr Res. 2012 May;137(1-3):66-72.

Place Hold on Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes.

The MATRICS consensus cognitive battery (MCCB): co-norming and standardization in Spain

By Bagney Lifante, Alexandra | Jiménez Arriero, Miguel Ángel | Moreno Ortega, Marta | Palomo Álvarez, Tomás | Rodríguez Jiménez, Roberto. Schizophrenia Research, 2012 . 134(2-3):279-84. , Formato Vancouver: Rodríguez-Jiménez R, Bagney A, García-Navarro C, Aparicio AI, López-Antón R, Moreno-Ortega M, et al. The MATRICS consensus cognitive battery (MCCB): co-norming and standardization in Spain. Schizophr Res. 2012 Feb;134(2-3):279-84.

Place Hold on The MATRICS consensus cognitive battery (MCCB): co-norming and standardization in Spain

The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia

By Hoenicka, Janet | Martínez Gras, María Isabel | Palomo Álvarez, Tomás | Rodríguez Jiménez, Roberto | Rubio Valladolid, Gabriel. Schizophrenia Research, 2011 . 128(1-3):15-22. , Formato Vancouver: Martínez Gras I, Pérez Nievas BG, García Bueno B, Madrigal JL, Andrés Esteban E, Rodríguez Jiménez R, et al. The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia. Schizophr Res. 2011;128(1-3):15-22.

Place Hold on The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia